Exchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
0.00% $0.0530
America/New_York / 2 mai 2024 @ 23:17
FUNDAMENTALS | |
---|---|
MarketCap: | 7.66 mill |
EPS: | 0.0100 |
P/E: | 5.30 |
Earnings Date: | Jul 25, 2024 |
SharesOutstanding: | 144.61 mill |
Avg Daily Volume: | 0.724 mill |
RATING 2024-05-03 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
Asset | n/a | n/a | n/a | n/a | n/a | n/a |
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
4.21x |
Company: PE 5.30 | sector: PE 1.258 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.14x |
Company: PE 5.30 | industry: PE 38.27 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0246 (-53.58%) $-0.0284 |
Date: 2024-05-02 |
Expected Trading Range (DAY) |
---|
$ 0.0470 - 0.0590 ( +/- 11.32%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $0.0530 (0.00% ) |
Volume | 0.0177 mill |
Avg. Vol. | 0.724 mill |
% of Avg. Vol | 2.45 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.